Discussion of the applicability of microarrays: profiling of leukemias.

Standard

Discussion of the applicability of microarrays: profiling of leukemias. / Haferlach, Torsten; Bacher, Ulrike; Kohlmann, Alexander; Haferlach, Claudia.

In: Methods Mol Biol, Vol. 509, 2009, p. 15-33.

Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

Harvard

APA

Vancouver

Haferlach T, Bacher U, Kohlmann A, Haferlach C. Discussion of the applicability of microarrays: profiling of leukemias. Methods Mol Biol. 2009;509:15-33.

Bibtex

@article{da1389b1ff674a1ebb613d80a2e2df72,
title = "Discussion of the applicability of microarrays: profiling of leukemias.",
abstract = "Leukemias are classified according to clinical, morphologic, and immunologic phenotypes, caused by specific genetic aberrations in association to distinct prognostic profiles. Usually the subtypes are defined using complementary laboratory methods, such as multiparameter flow cytometry, cytogenetics in combination with fluorescence in situ hybridization, and molecular methods such as the polymerase chain reaction. The genetic variations of the different subtypes lead to distinct changes also in gene expression, which is comprehensively analysed by DNA microarrays. Thus, first gene expression profiling studies showed that analysis with whole-genome DNA microarrays leads to a prediction accuracy of 95.6% with respect to the classical methods, and even allowed a further distinction of subtypes. It is expected that diagnostic strategies can be optimized with this new technology and that the understanding of the molecular pathogenesis of leukemias will be significantly improved. This could also lead to the identification of new targets for future drugs.",
author = "Torsten Haferlach and Ulrike Bacher and Alexander Kohlmann and Claudia Haferlach",
year = "2009",
language = "Deutsch",
volume = "509",
pages = "15--33",
journal = "Methods Mol Biol",
issn = "1064-3745",
publisher = "Humana Press",

}

RIS

TY - JOUR

T1 - Discussion of the applicability of microarrays: profiling of leukemias.

AU - Haferlach, Torsten

AU - Bacher, Ulrike

AU - Kohlmann, Alexander

AU - Haferlach, Claudia

PY - 2009

Y1 - 2009

N2 - Leukemias are classified according to clinical, morphologic, and immunologic phenotypes, caused by specific genetic aberrations in association to distinct prognostic profiles. Usually the subtypes are defined using complementary laboratory methods, such as multiparameter flow cytometry, cytogenetics in combination with fluorescence in situ hybridization, and molecular methods such as the polymerase chain reaction. The genetic variations of the different subtypes lead to distinct changes also in gene expression, which is comprehensively analysed by DNA microarrays. Thus, first gene expression profiling studies showed that analysis with whole-genome DNA microarrays leads to a prediction accuracy of 95.6% with respect to the classical methods, and even allowed a further distinction of subtypes. It is expected that diagnostic strategies can be optimized with this new technology and that the understanding of the molecular pathogenesis of leukemias will be significantly improved. This could also lead to the identification of new targets for future drugs.

AB - Leukemias are classified according to clinical, morphologic, and immunologic phenotypes, caused by specific genetic aberrations in association to distinct prognostic profiles. Usually the subtypes are defined using complementary laboratory methods, such as multiparameter flow cytometry, cytogenetics in combination with fluorescence in situ hybridization, and molecular methods such as the polymerase chain reaction. The genetic variations of the different subtypes lead to distinct changes also in gene expression, which is comprehensively analysed by DNA microarrays. Thus, first gene expression profiling studies showed that analysis with whole-genome DNA microarrays leads to a prediction accuracy of 95.6% with respect to the classical methods, and even allowed a further distinction of subtypes. It is expected that diagnostic strategies can be optimized with this new technology and that the understanding of the molecular pathogenesis of leukemias will be significantly improved. This could also lead to the identification of new targets for future drugs.

M3 - SCORING: Zeitschriftenaufsatz

VL - 509

SP - 15

EP - 33

JO - Methods Mol Biol

JF - Methods Mol Biol

SN - 1064-3745

ER -